CalciMedica, Inc.
CALCHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeCalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company carries a $13.8M market cap, placing it firmly in the micro-cap category. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Market Cap
$13.8M
Beta
1.01
P/E (TTM)
—
P/E (Fwd)
-1.24
EPS (TTM)
$-6.85
EPS (Fwd)
$-1.63
ROE
-365.7%
ROA
-63.6%
Cash
$18.6M
Total Debt
$9.2M
Free CF
-$10.5M
52W Change
-87.6%
Annual Financials
Cash vs Debt
Where CALC stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CALC finished 187.67% above its 150-day moving average ($0.73) and 18.64% above its 200-day moving average ($1.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CALC overbought or oversold?
At the September 3, 2026 close, CALC's RSI(14) was 82.7, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $18.6M in cash and $9.2M in debt, CALC maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$10.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -365.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, CALC has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CALC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.